Evaluate a Norstella company
Evaluate a Norstella company
Back to all episodes
Advanced Therapies

Advanced Therapies

Advanced therapy pipeline growth has slowed from 25% to 7%, yet 2026 dealmaking is holding pace and start-up funding is rising. Evaluate’s experts discuss the state of the pipeline, the therapy areas in focus, and the companies investing in a high-risk space.
23 minutes

–

On demand

AM
Amanda Micklus
Senior Consultant
SE
Sydney Enokawa
Content Strategy Specialist

Register free to unlock

Full episode video

Companion short report

Blog post & thought leadership

Scroll down to register — one form unlocks everything on this page.

Register for free access
Notify me when new episodes are dropping







Episode Video

Watch now

23 minutes

What the episode covers

  • Why advanced therapies make up just 2% of launched drugs despite a deep early pipeline.
  • Where oncology dominates cell therapy and where gene and RNA therapies spread wider.
  • How in vivo CAR-T could change the cost and reach of cell therapy.
  • Which companies lead the pipeline, and which products earn the most revenue today.
  • What 2026’s biggest deals reveal about where dealmakers are placing their bets.
  • The regulatory and commercial decision driving commercial expectations .

Additional content

Go Deeper

Report

Report

The Next Wave: In Vivo CAR-T and the Changing Shape of Advanced Therapies.

In vivo CAR-T is attracting major 2026 deals as pipeline growth settles at 7%. See who is building, who is selling, and what comes next.
Blog

Blog

Advanced Therapies Enter a More Selective Cycle

Short on time? Check out the blog post. Which advanced therapies will win in a more selective cycle? Explore in vivo CAR-T, pipeline and dealmaking.

Up next in the series

Evaluate Spotlight: Metabolic

Mark Lansdell & Jack Hughes
Notify me when available
All episodes

Evaluate Consulting

Data into direction. Partnership into purpose.

Want to go deeper? Evaluate’s consulting team provides bespoke analysis on market sizing, pipeline strategy, BD&L, and competitive intelligence.

Find out more
Evaluate White Logo
Instagram Linkedin